PARIS (Thomson Financial) - Sanofi-Aventis said it has upgraded its European prescription labelling for its Acomplia weight-loss and diabetes treatment to contraindicate it for patients with ongoing major depressive illness and/or ongoing anti-depressive treatment.
From: www.iii.co.uk
AFX UK Focus) 2007-07-19 16:57 GMT: Sanofi updates Acomplia EU labelling to warn on depression;EMEA opinion positive
Posted by Ruslan Abuzant at 11:32 AM
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment